PerkinElmer Announces HCA ImagAmp™ Reagent Kits to Improve High Content Screening and Analysis

Global leader in assay solutions releases signal amplification system to improve sensitivity in automated detection of cellular events to speed disease and therapeutic research

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the release of the HCA ImagAmp™ reagent kit for high content screening and analysis applications in life sciences and drug discovery research.

“For instance, the sensitivity enhancement provided by HCA ImagAmp technology enables earlier detection of critical cellular events such as apoptosis, speeding disease and therapeutic research.”

High content analysis (HCA), also known as image cytometry, is a powerful tool for automated cell biology that allows unbiased imaging and analysis of cellular samples. The technique is widely used in a variety of research areas including cell differentiation, cell toxicity, programmed cell death, drug discovery, protein expression and signaling pathway analysis.

“The new HCA ImagAmp reagent kit is designed to allow researchers to measure proteins of interest that were previously undetectable using standard methods of detection in high content screening,” said Martina Bielefeld-Sévigny, PhD, vice president and general manager, Bio-discovery, PerkinElmer. “For instance, the sensitivity enhancement provided by HCA ImagAmp technology enables earlier detection of critical cellular events such as apoptosis, speeding disease and therapeutic research.”

Flexible and efficient, the HCA ImagAmp™ platform offers faster detection with high quality imaging capability, along with easy to use features for integrating into workflows. The kits leverage PerkinElmer’s proprietary Tyramide Signal Amplification™ (TSA) technology to deliver unprecedented sensitivity without compromising image resolution. HCA ImagAmp technology can be added to virtually any assay protocol with a simple 10-minute incubation step. The HCA ImagAmp kits are designed to allow researchers to achieve consistent detection of weakly expressed targets and reach their HCS research goals sooner. The new kits are platform-agnostic and designed to provide superior image resolution on virtually any high content screening instrument, including PerkinElmer’s Opera^® and Operetta^® Imaging Systems.

Key features of the HCA ImagAmp technology enable end-users to:

• Quantify analytes of interest at previously undetectable levels
• Extend quantitative range and improve reliability of results
• Conserve primary antibody while improving assay specificity
• Reduce exposure time for higher throughput
• Enhance image resolution with robust signal

To learn more, please visit: www.perkinelmer.com\HCAImagAmp.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.